Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Is iluvien off patent?

See the DrugPatentWatch profile for iluvien

Short answer:
No – Iluvien is still under patent protection in the United States, and there are no approved generic versions of the implant.


Why Iluvien is still “on‑patent”

Aspect Status Notes
Active ingredient (fluocinolone acetonide) Off‑patent in the sense that the chemical itself has been on the market for decades, so generic manufacturers can sell the drug in other formulations. The generic fluocinolone acetonide exists (e.g., oral or injectable preparations for other indications), but it does not replace the Iluvien implant.
Device (0.19 mg intravitreal implant) Still protected by patents covering the delivery system, release profile, and method of use. The key patents are the US 7,777,610 (covering the 0.19 mg implant) and related patents filed in the early 2000s. These expire around 2024‑2025, after which a generic device could theoretically be made.
Brand ownership Alcon (a Novartis subsidiary) holds the trademark and exclusive commercial rights. Even after patent expiry, the company could still defend the brand name through trademark law and market dominance.

What this means for patients and prescribers

  • No generic implants are currently available in the U.S. or most other markets.
  • Insurance and reimbursement are handled through Alcon’s pricing structure for Iluvien.
  • If/when the patents expire (likely 2024‑2025), other manufacturers may seek to file for approval of a comparable implant, which could reduce costs over time.

Bottom line

  • Iluvien is not off patent.
  • The active drug itself is generic, but the patented delivery system and method of use keep Iluvien as a brand‑exclusive product for the foreseeable future.


Other Questions About Iluvien :

Iluvien not approved in japan? Iluvien approval japan? Iluvien japan pmda? Iluvien japan approval? Iluvien price? Iluvien coupon? Iluvien cost?